{
  "legislationId": "119_S_4220",
  "lastUpdate": "2026-04-13T14:56:56.897Z",
  "history": [
    {
      "timestamp": "2026-04-13T14:56:56.897Z",
      "source_url": "https://www.congress.gov/119/bills/s4220/BILLS-119s4220is.htm",
      "model": "gemini-flash-lite-latest",
      "prompt_sent": "\nROLE: Fact Checker.\nZADANIE: Porównaj SOURCE (oryginał) i SUMMARY (streszczenie przygotowane przez inne AI).\n\nTwoim celem jest wykrycie \"ZMYŚLONYCH KONKRETÓW\" (Fabricated Entities) w SUMMARY.\n\nSOURCE:\n[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [S. 4220 Introduced in Senate (IS)] <DOC> 119th CONGRESS 2d Session S. 4220 To amend title 38, United States Code, to establish within the Veterans Health Administration an Office of Novel Therapeutics, and for other purposes. _______________________________________________________________________ IN THE SENATE OF THE UNITED STATES March 26, 2026 Mr. Sheehy (for himself, Mr. Gallego, Ms. Duckworth, and Mr. Boozman) introduced the following bill; which was read twice and referred to the Committee on Veterans' Affairs _______________________________________________________________________ A BILL To amend title 38, United States Code, to establish within the Veterans Health Administration an Office of Novel Therapeutics, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Veterans Health Administration Novel Therapeutics Preparedness Act''. SEC. 2. FINDINGS. Congress finds the following: (1) Emerging therapeutic interventions, including certain psychedelic-assisted therapies under evaluation by the Food and Drug Administration as of the date of the enactment of this Act, may significantly alter the treatment landscape for post- traumatic stress disorder, depression, and other mental health conditions affecting veterans. (2) The administration of certain emerging therapies may require intensive clinical engagement, interdisciplinary teams, dedicated clinical space, structured preparation, and post- treatment integration that differ substantially from traditional outpatient mental health services. (3) The Department of Veterans Affairs is uniquely positioned to deliver integrated, veteran-centered care that combines medical, mental health, and peer support services within a single system of care. (4) Absent centralized governance and implementation planning, the Department may face delays, safety risks, or inconsistent access following regulatory approval of such therapies. (5) Establishing a dedicated Office of Novel Therapeutics will ensure that the Department is prepared to responsibly evaluate, research, and implement emerging treatment modalities consistent with patient safety and evidence-based practice. SEC. 3. ESTABLISHMENT OF OFFICE OF NOVEL THERAPEUTICS WITHIN VETERANS HEALTH ADMINISTRATION. (a) Establishment.-- (1) In general.--Chapter 73 of title 38, United States Code, is amended by adding at the end the following new subchapter: ``Subchapter VI--Novel Therapeutics ``Sec. 7391. Definitions ``In this subchapter: ``(1) Center of excellence.--The term `center of excellence' means a medical center of the Department designated under section 7394 of this title as a center of excellence for novel therapeutics to advance research, training, and implementation of emerging therapeutic interventions. ``(2) Emerging therapeutic intervention.--The term `emerging therapeutic intervention' means a pharmacological, biological, or other therapeutic modality under evaluation or review by the Food and Drug Administration. ``Sec. 7392. Office of Novel Therapeutics ``(a) Establishment.--There is established within the Veterans Health Administration, under the Office of the Under Secretary for Health, an Office of Novel Therapeutics (in this section referred to as the `Office'). ``(b) Director.--The head of the Office shall be the Director of the Office of Novel Therapeutics, who shall be appointed by the Under Secretary for Health and who shall-- ``(1) possess demonstrated expertise in clinical research and implementation science; and ``(2) report directly to the Under Secretary for Health. ``(c) Coordinating Authority.--The Office shall serve as the primary coordinating authority within the Veterans Health Administration for matters relating to emerging and novel therapeutic interventions. ``(d) Duties.--The Office shall-- ``(1) develop and oversee national policy, guidance, and clinical standards for the evaluation, research, and potential implementation by the Veterans Health Administration of emerging and novel therapeutic interventions for mental health conditions affecting veterans; ``(2) develop a national clinical model for the administration of intensive therapeutic interventions, including structured preparation, monitored administration, and post-administration integration; ``(3) develop guidance regarding patient eligibility and candidacy for emerging therapeutic interventions, ensuring that utilization management or step therapy requirements do not unduly restrict access where clinically appropriate; ``(4) develop implementation-readiness plans for therapies that may receive approval from the Food and Drug Administration, including-- ``(A) facility infrastructure requirements; ``(B) interdisciplinary team composition standards; ``(C) allocation of protected clinical time necessary to safely administer intensive therapeutic interventions, including full session and integration requirements; ``(D) patient safety and adverse event monitoring and response protocols; and ``(E) integration with suicide prevention, post- traumatic stress disorder, and substance use disorder programs; ``(5) conduct a workforce-readiness assessment to identify clinicians and peer support specialists with prior training or certification relevant to emerging therapeutic interventions and gaps in training, supervision, and clinical capacity necessary to support safe and effective implementation of such interventions; ``(6) establish national training and credentialing standards for clinicians administering novel therapeutics; ``(7) develop a standardized, competency-based training framework for clinicians and peer support specialists participating in emerging therapeutic interventions, including preparation, monitored administration, integration, safety monitoring, interdisciplinary collaboration, and culturally competent care; ``(8) distinguish between research protocols and clinical implementation standards to ensure that patient care models are not constrained solely by sponsor-driven research design; ``(9) coordinate with the Office of Research and Development-- ``(A) to align research priorities with implementation-readiness needs; ``(B) to recommend specialized review pathways for research involving emerging therapeutic interventions; and ``(C) to develop standards for allocation of protected research time for clinicians participating in research involving emerging therapeutic interventions, including clarification that patients seen under approved research protocols shall be counted toward standard clinical productivity metrics; ``(10) develop guidance to ensure continuity of care, including-- ``(A) post-administration integration services; ``(B) incorporation of peer support specialists; and ``(C) coordination with community-based organizations for aftercare support as appropriate; ``(11) identify not fewer than one medical center in each Veterans Integrated Service Network to develop infrastructure and workforce-readiness for emerging therapeutic models; and ``(12) establish criteria for the designation of centers of excellence and oversee compliance with national standards. ``Sec. 7393. Clinical Implementation Program for Emerging Therapeutics ``(a) Establishment.--The Secretary, acting through the Office of Novel Therapeutics, shall establish a Clinical Implementation Program for Emerging Therapeutics (in this section referred to as the `Program') to evaluate the effectiveness, feasibility, safety, and scalability of emerging therapeutic interventions within the Department. ``(b) Purpose.--The Program shall-- ``(1) utilize effectiveness-implementation hybrid models to evaluate both clinical outcomes and real-world implementation factors with respect to emerging therapeutic interventions; ``(2) test and refine care delivery models, including patient eligibility criteria, safety protocols, interdisciplinary team models, and post-administration integration services; ``(3) generate real-world evidence to inform potential systemwide adoption; and ``(4) assess workforce, infrastructure, cost, and operational requirements necessary for broader implementation. ``(c) Covered Conditions.--In carrying out the Program, the Secretary may prioritize one or more brain or mental health conditions affecting veterans, including-- ``(1) post-traumatic stress disorder; ``(2) treatment-resistant depression; ``(3) substance use disorders; ``(4) suicidality; ``(5) traumatic brain injury; ``(6) repetitive low-level blast exposure; ``(7) chronic pain; ``(8) co-occurring conditions; and ``(9) other clinically appropriate conditions as determined appropriate by the Secretary. ``(d) Site Selection.--The Secretary may conduct the Program at-- ``(1) one or more centers of excellence; and ``(2) such other medical centers as the Secretary determines appropriate. ``Sec. 7394. Centers of excellence for novel therapeutics ``(a) Designation.--The Secretary may designate one or more medical centers of the Department as centers of excellence for novel therapeutics. ``(b) Functions.--Each center of excellence designated under subsection (a) shall-- ``(1) serve as a national leader in research, clinical training, and implementation of emerging therapeutic interventions; ``(2) develop and disseminate best practices and clinical standards across the Veterans Health Administration; ``(3) provide technical assistance and training to other medical centers of the Department; ``(4) integrate interdisciplinary care models, including peer support and post-administration integration services; ``(5) incorporate veteran advisory input into program development; and ``(6) coordinate with academic affiliates and external research partners, as appropriate. ``(c) Coordination.--Centers of excellence designated under subsection (a) shall operate in coordination with, and under standards established by, the Office of Novel Therapeutics. ``Sec. 7395. Veteran Advisory Committee on Novel Therapeutics ``(a) Establishment.--The Secretary shall establish a Veteran Advisory Committee on Novel Therapeutics (in this section referred to as the `Committee') to advise the Office of Novel Therapeutics. ``(b) Membership.--The Secretary shall select the members of the Committee, which shall include the following: ``(1) Veterans with lived experience of mental health treatment furnished by the Department. ``(2) Veterans who have participated in clinical research involving emerging therapeutic interventions, as applicable. ``(3) Family members or caregivers of veterans described in paragraph (1) or (2). ``(4) Representatives from academic institutions affiliated with the Department with expertise in clinical research, behavioral health, or emerging therapeutic interventions. ``(5) Subject matter experts as determined appropriate by the Secretary. ``(c) Duties.--With respect to the use of novel therapeutics, the Committee shall provide input on-- ``(1) patient safety considerations; ``(2) informed consent practices; ``(3) implementation and access barriers; and ``(4) patient-centered care design. ``Sec. 7396. Interagency coordination ``In carrying out this subchapter, the Secretary shall coordinate with the Secretary of Health and Human Services, the Commissioner of Food and Drugs, the Administrator of the Centers for Medicare & Medicaid Services, the Secretary of Defense, and the Administrator of the Drug Enforcement Administration to support-- ``(1) regulatory readiness; ``(2) development of reimbursement and billing pathways; ``(3) scheduling and rescheduling considerations, as appropriate; and ``(4) shared data infrastructure for monitoring safety, quality, and outcomes. ``Sec. 7397. Annual report ``Not less frequently than annually, the Secretary shall submit to Congress a report describing-- ``(1) research activities of the Department relating to emerging therapeutic interventions; ``(2) clinical outcomes and patient-reported outcomes under the Clinical Implementation Program for Emerging Therapeutics under section 7393 of this title; ``(3) safety events and adverse outcomes; ``(4) workforce readiness and training capacity; ``(5) implementation barriers, including staffing, procurement, and infrastructure needs; and ``(6) recommendations for legislative or administrative action relating to novel therapeutics.''. (2) Clerical amendment.--The table of sections at the beginning of chapter 73 of such title is amended by adding at the end the following: ``subchapter vi--novel therapeutics ``Sec. ``7391. Definitions. ``7392. Office of Novel Therapeutics. ``7393. Clinical Implementation Program for Emerging Therapeutics. ``7394. Centers of excellence for novel therapeutics. ``7395. Veteran Advisory Committee on Novel Therapeutics. ``7396. Interagency coordination. ``7397. Annual report.''. (b) National Preparedness and Implementation Strategy.--Not later than 180 days after the date of the enactment of this Act, the Secretary of Veterans Affairs shall submit to Congress a national preparedness and implementation strategy of the Veterans Health Administration for emerging mental health therapeutics, including-- (1) workforce capacity assessments; (2) facility modification needs; (3) projected timelines for phased implementation; and (4) barriers to implementation. <all>\n\nSUMMARY TO EVALUATE:\nTitle: Modern Mental Health Therapies for Veterans: New Office and Innovative Treatments\nSummary: The act establishes a dedicated Office of Novel Therapeutics to prepare the veterans' healthcare system for the safe implementation of innovative treatments, such as psychedelic-assisted therapies. These changes aim to provide faster access to modern help for depression, PTSD, and other mental health conditions.\nKey Points: Establishment of the Office of Novel Therapeutics within the Veterans Health Administration., Development of standards for new treatment methods, including therapies requiring intensive clinical care., Creation of a veteran advisory committee to give veterans and their families a voice in care design., Designation of specialized centers of excellence for research and training in novel therapies., Ensuring continuity of care through peer support and coordination with community organizations.\n\nZASADY OCENY:\n1. Sprawdź wszystkie LICZBY, DATY i KWOTY w SUMMARY. Jeśli którejś brakuje w SOURCE -> is_valid: false.\n2. Sprawdź wszystkie NAZWISKA, ORGANIZACJE i MIEJSCA w SUMMARY. Jeśli którejś brakuje w SOURCE -> is_valid: false.\n3. Sprawdź wszystkie konkretne DZIAŁANIA PRAWNE . Jeśli tego mechanizmu nie ma w SOURCE -> is_valid: false.\n\nWAŻNE: Abstrakcyjne pojęcia (np. \"transparentność\", \"zaufanie\") są dozwolone jako wnioski.\n\nOUTPUT (JSON):\n{\n  \"is_valid\": true/false,\n  \"issue\": \"fabricated_entity\" / \"contradiction\" / \"none\"\n}\n\nWYMAGANIA FORMATOWANIA:\n1. Odpowiedz WYŁĄCZNIE surowym obiektem JSON.\n2. NIE używaj bloków kodu Markdown.\n3. NIE dodawaj żadnych wstępów ani wyjaśnień przed ani po JSONie.\n4. JSON musi być poprawny i gotowy do parsowania.\n\n",
      "ai_response_raw": "{\n  \"is_valid\": true,\n  \"issue\": \"none\"\n}"
    },
    {
      "timestamp": "2026-04-13T14:24:11.695Z",
      "source_url": "https://www.congress.gov/119/bills/s4220/BILLS-119s4220is.htm",
      "model": "gemini-flash-latest",
      "prompt_sent": "\nJesteś ekspertem od prawa Stanów Zjednoczonych, który ma za zadanie analizować dokumenty ustaw, uchwał oraz innych dokumentów legislacyjnych, a następnie przygotowywać z nich informacje w przystępny sposób dla obywateli. Twoim celem jest przedstawienie informacji tak, aby obywatele mogli sami ocenić wpływ legislacji na ich życie, nawet bez posiadania specjalistycznej wiedzy legislacyjnej. Skup się na faktach i obiektywnych skutkach wprowadzanych zmian, unikając wartościowania i osobistych opinii. Wszelki żargon prawny jest zabroniony. Prezentuj informacje w jasny, zwięzły i angażujący sposób, tak aby były zrozumiałe dla osoby bez wykształcenia prawniczego. Unikaj długich, złożonych zdań. Zamiast pisać \"projekt ma na celu nowelizację kodeksu podatkowego...\", napisz \"Zmiany w podatkach: nowe ulgi i obowiązki dla...\". Kontynuuj swoją pracę, dopóki nie rozwiążesz swojego zadania. Jeśli nie masz pewności co do generowanej treści, przeanalizuj dokument ponownie – nie zgaduj. Rozplanuj dobrze swoje zadanie przed przystąpieniem do niego. W podsumowaniu i kluczowych punktach, jeśli to możliwe i uzasadnione, podkreśl, jakie konkretne korzyści lub skutki (pozytywne lub negatywne) wprowadza ustawa dla życia codziennego obywateli, ich praw i obowiązków, finansów osobistych, bezpieczeństwa i innych ważnych kwestii (np. kategorycznych zakazów i nakazów czy najważniejszych konkretnych alokacji finansowych i terytorialnych).\n\nTwoja odpowiedź MUSI być w formacie JSON - i zawierać następujące klucze.\nZanim zwrócisz odpowiedź, dokładnie zweryfikuj, czy cała struktura JSON jest w 100% poprawna, włącznie ze wszystkimi przecinkami, nawiasami klamrowymi, kwadratowymi oraz cudzysłowami. Błędny JSON jest nieakceptowalny i uniemożliwi przetworzenie Twojej pracy.\n\nPrzeanalizuj dokładnie poniższy tekst dokumentu prawnego. To jest treść, na podstawie której masz wygenerować podsumowanie i kluczowe punkty:\n--- POCZĄTEK DOKUMENTU ---\n[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [S. 4220 Introduced in Senate (IS)] <DOC> 119th CONGRESS 2d Session S. 4220 To amend title 38, United States Code, to establish within the Veterans Health Administration an Office of Novel Therapeutics, and for other purposes. _______________________________________________________________________ IN THE SENATE OF THE UNITED STATES March 26, 2026 Mr. Sheehy (for himself, Mr. Gallego, Ms. Duckworth, and Mr. Boozman) introduced the following bill; which was read twice and referred to the Committee on Veterans' Affairs _______________________________________________________________________ A BILL To amend title 38, United States Code, to establish within the Veterans Health Administration an Office of Novel Therapeutics, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Veterans Health Administration Novel Therapeutics Preparedness Act''. SEC. 2. FINDINGS. Congress finds the following: (1) Emerging therapeutic interventions, including certain psychedelic-assisted therapies under evaluation by the Food and Drug Administration as of the date of the enactment of this Act, may significantly alter the treatment landscape for post- traumatic stress disorder, depression, and other mental health conditions affecting veterans. (2) The administration of certain emerging therapies may require intensive clinical engagement, interdisciplinary teams, dedicated clinical space, structured preparation, and post- treatment integration that differ substantially from traditional outpatient mental health services. (3) The Department of Veterans Affairs is uniquely positioned to deliver integrated, veteran-centered care that combines medical, mental health, and peer support services within a single system of care. (4) Absent centralized governance and implementation planning, the Department may face delays, safety risks, or inconsistent access following regulatory approval of such therapies. (5) Establishing a dedicated Office of Novel Therapeutics will ensure that the Department is prepared to responsibly evaluate, research, and implement emerging treatment modalities consistent with patient safety and evidence-based practice. SEC. 3. ESTABLISHMENT OF OFFICE OF NOVEL THERAPEUTICS WITHIN VETERANS HEALTH ADMINISTRATION. (a) Establishment.-- (1) In general.--Chapter 73 of title 38, United States Code, is amended by adding at the end the following new subchapter: ``Subchapter VI--Novel Therapeutics ``Sec. 7391. Definitions ``In this subchapter: ``(1) Center of excellence.--The term `center of excellence' means a medical center of the Department designated under section 7394 of this title as a center of excellence for novel therapeutics to advance research, training, and implementation of emerging therapeutic interventions. ``(2) Emerging therapeutic intervention.--The term `emerging therapeutic intervention' means a pharmacological, biological, or other therapeutic modality under evaluation or review by the Food and Drug Administration. ``Sec. 7392. Office of Novel Therapeutics ``(a) Establishment.--There is established within the Veterans Health Administration, under the Office of the Under Secretary for Health, an Office of Novel Therapeutics (in this section referred to as the `Office'). ``(b) Director.--The head of the Office shall be the Director of the Office of Novel Therapeutics, who shall be appointed by the Under Secretary for Health and who shall-- ``(1) possess demonstrated expertise in clinical research and implementation science; and ``(2) report directly to the Under Secretary for Health. ``(c) Coordinating Authority.--The Office shall serve as the primary coordinating authority within the Veterans Health Administration for matters relating to emerging and novel therapeutic interventions. ``(d) Duties.--The Office shall-- ``(1) develop and oversee national policy, guidance, and clinical standards for the evaluation, research, and potential implementation by the Veterans Health Administration of emerging and novel therapeutic interventions for mental health conditions affecting veterans; ``(2) develop a national clinical model for the administration of intensive therapeutic interventions, including structured preparation, monitored administration, and post-administration integration; ``(3) develop guidance regarding patient eligibility and candidacy for emerging therapeutic interventions, ensuring that utilization management or step therapy requirements do not unduly restrict access where clinically appropriate; ``(4) develop implementation-readiness plans for therapies that may receive approval from the Food and Drug Administration, including-- ``(A) facility infrastructure requirements; ``(B) interdisciplinary team composition standards; ``(C) allocation of protected clinical time necessary to safely administer intensive therapeutic interventions, including full session and integration requirements; ``(D) patient safety and adverse event monitoring and response protocols; and ``(E) integration with suicide prevention, post- traumatic stress disorder, and substance use disorder programs; ``(5) conduct a workforce-readiness assessment to identify clinicians and peer support specialists with prior training or certification relevant to emerging therapeutic interventions and gaps in training, supervision, and clinical capacity necessary to support safe and effective implementation of such interventions; ``(6) establish national training and credentialing standards for clinicians administering novel therapeutics; ``(7) develop a standardized, competency-based training framework for clinicians and peer support specialists participating in emerging therapeutic interventions, including preparation, monitored administration, integration, safety monitoring, interdisciplinary collaboration, and culturally competent care; ``(8) distinguish between research protocols and clinical implementation standards to ensure that patient care models are not constrained solely by sponsor-driven research design; ``(9) coordinate with the Office of Research and Development-- ``(A) to align research priorities with implementation-readiness needs; ``(B) to recommend specialized review pathways for research involving emerging therapeutic interventions; and ``(C) to develop standards for allocation of protected research time for clinicians participating in research involving emerging therapeutic interventions, including clarification that patients seen under approved research protocols shall be counted toward standard clinical productivity metrics; ``(10) develop guidance to ensure continuity of care, including-- ``(A) post-administration integration services; ``(B) incorporation of peer support specialists; and ``(C) coordination with community-based organizations for aftercare support as appropriate; ``(11) identify not fewer than one medical center in each Veterans Integrated Service Network to develop infrastructure and workforce-readiness for emerging therapeutic models; and ``(12) establish criteria for the designation of centers of excellence and oversee compliance with national standards. ``Sec. 7393. Clinical Implementation Program for Emerging Therapeutics ``(a) Establishment.--The Secretary, acting through the Office of Novel Therapeutics, shall establish a Clinical Implementation Program for Emerging Therapeutics (in this section referred to as the `Program') to evaluate the effectiveness, feasibility, safety, and scalability of emerging therapeutic interventions within the Department. ``(b) Purpose.--The Program shall-- ``(1) utilize effectiveness-implementation hybrid models to evaluate both clinical outcomes and real-world implementation factors with respect to emerging therapeutic interventions; ``(2) test and refine care delivery models, including patient eligibility criteria, safety protocols, interdisciplinary team models, and post-administration integration services; ``(3) generate real-world evidence to inform potential systemwide adoption; and ``(4) assess workforce, infrastructure, cost, and operational requirements necessary for broader implementation. ``(c) Covered Conditions.--In carrying out the Program, the Secretary may prioritize one or more brain or mental health conditions affecting veterans, including-- ``(1) post-traumatic stress disorder; ``(2) treatment-resistant depression; ``(3) substance use disorders; ``(4) suicidality; ``(5) traumatic brain injury; ``(6) repetitive low-level blast exposure; ``(7) chronic pain; ``(8) co-occurring conditions; and ``(9) other clinically appropriate conditions as determined appropriate by the Secretary. ``(d) Site Selection.--The Secretary may conduct the Program at-- ``(1) one or more centers of excellence; and ``(2) such other medical centers as the Secretary determines appropriate. ``Sec. 7394. Centers of excellence for novel therapeutics ``(a) Designation.--The Secretary may designate one or more medical centers of the Department as centers of excellence for novel therapeutics. ``(b) Functions.--Each center of excellence designated under subsection (a) shall-- ``(1) serve as a national leader in research, clinical training, and implementation of emerging therapeutic interventions; ``(2) develop and disseminate best practices and clinical standards across the Veterans Health Administration; ``(3) provide technical assistance and training to other medical centers of the Department; ``(4) integrate interdisciplinary care models, including peer support and post-administration integration services; ``(5) incorporate veteran advisory input into program development; and ``(6) coordinate with academic affiliates and external research partners, as appropriate. ``(c) Coordination.--Centers of excellence designated under subsection (a) shall operate in coordination with, and under standards established by, the Office of Novel Therapeutics. ``Sec. 7395. Veteran Advisory Committee on Novel Therapeutics ``(a) Establishment.--The Secretary shall establish a Veteran Advisory Committee on Novel Therapeutics (in this section referred to as the `Committee') to advise the Office of Novel Therapeutics. ``(b) Membership.--The Secretary shall select the members of the Committee, which shall include the following: ``(1) Veterans with lived experience of mental health treatment furnished by the Department. ``(2) Veterans who have participated in clinical research involving emerging therapeutic interventions, as applicable. ``(3) Family members or caregivers of veterans described in paragraph (1) or (2). ``(4) Representatives from academic institutions affiliated with the Department with expertise in clinical research, behavioral health, or emerging therapeutic interventions. ``(5) Subject matter experts as determined appropriate by the Secretary. ``(c) Duties.--With respect to the use of novel therapeutics, the Committee shall provide input on-- ``(1) patient safety considerations; ``(2) informed consent practices; ``(3) implementation and access barriers; and ``(4) patient-centered care design. ``Sec. 7396. Interagency coordination ``In carrying out this subchapter, the Secretary shall coordinate with the Secretary of Health and Human Services, the Commissioner of Food and Drugs, the Administrator of the Centers for Medicare & Medicaid Services, the Secretary of Defense, and the Administrator of the Drug Enforcement Administration to support-- ``(1) regulatory readiness; ``(2) development of reimbursement and billing pathways; ``(3) scheduling and rescheduling considerations, as appropriate; and ``(4) shared data infrastructure for monitoring safety, quality, and outcomes. ``Sec. 7397. Annual report ``Not less frequently than annually, the Secretary shall submit to Congress a report describing-- ``(1) research activities of the Department relating to emerging therapeutic interventions; ``(2) clinical outcomes and patient-reported outcomes under the Clinical Implementation Program for Emerging Therapeutics under section 7393 of this title; ``(3) safety events and adverse outcomes; ``(4) workforce readiness and training capacity; ``(5) implementation barriers, including staffing, procurement, and infrastructure needs; and ``(6) recommendations for legislative or administrative action relating to novel therapeutics.''. (2) Clerical amendment.--The table of sections at the beginning of chapter 73 of such title is amended by adding at the end the following: ``subchapter vi--novel therapeutics ``Sec. ``7391. Definitions. ``7392. Office of Novel Therapeutics. ``7393. Clinical Implementation Program for Emerging Therapeutics. ``7394. Centers of excellence for novel therapeutics. ``7395. Veteran Advisory Committee on Novel Therapeutics. ``7396. Interagency coordination. ``7397. Annual report.''. (b) National Preparedness and Implementation Strategy.--Not later than 180 days after the date of the enactment of this Act, the Secretary of Veterans Affairs shall submit to Congress a national preparedness and implementation strategy of the Veterans Health Administration for emerging mental health therapeutics, including-- (1) workforce capacity assessments; (2) facility modification needs; (3) projected timelines for phased implementation; and (4) barriers to implementation. <all>\n--- KONIEC DOKUMENTU ---\n\nPAMIĘTAJ: Twoja odpowiedź MUSI być wyłącznie poprawnym obiektem JSON. Nie dodawaj żadnych dodatkowych znaków, komentarzy ani tekstu przed znacznikiem '{' ani po znaczniku '}'. Cała odpowiedź musi być parsowalna jako JSON.\nNa podstawie POWYŻSZEGO dokumentu, wypełnij poniższą strukturę JSON:\nOto struktura JSON, której oczekuję (wypełnij ją treścią):\n{\n  \"pl_ai_title\": \"Nowy, krótki tytuł dla aktu prawnego po polsku, oddający sedno wprowadzanych zmian (np. maksymalnie 10-12 słów).\",\n  \"pl_summary\": \"2-3 zdania zwięzłego podsumowania treści aktu prawnego po polsku, napisane z perspektywy wpływu na życie codzienne obywateli.\",\n  \"pl_key_points\": [\n    \"Pierwszy krótki punkt po polsku dotyczący najważniejszych wprowadzanych rozwiązań lub zmian.\",\n    \"Drugi krótki punkt po polsku...\"\n  ],\n  \"eng_ai_title\": \"A new, short title for the legal act in English, capturing the essence of the changes (e.g., max 10-12 words).\",\n  \"eng_summary\": \"2-3 sentences summarizing the legal act in English, from the perspective of its impact on citizens' daily lives.\",\n  \"eng_key_points\": [\n    \"First short bullet point in English regarding the most important solutions or changes being introduced.\",\n    \"Second short bullet point in English...\"\n  ],\n  \"de_ai_title\": \"Ein neuer, kurzer Titel für das Rechtsdokument auf Deutsch, der den Kern der Änderungen erfasst (z.B. max. 10-12 Wörter).\",\n  \"de_summary\": \"2-3 Sätze Zusammenfassung des Rechtsdokuments auf Deutsch, aus der Perspektive seiner Auswirkungen auf das tägliche Leben der Bürger.\",\n  \"de_key_points\": [\n    \"Erster kurzer Stichpunkt auf Deutsch zu den wichtigsten eingeführten Lösungen oder Änderungen.\",\n    \"Zweiter kurzer Stichpunkt auf Deutsch...\"\n  ],\n  \"fr_ai_title\": \"Un nouveau titre court pour l'acte juridique en français, saisissant l'essence des changements (par exemple, 10-12 mots maximum).\",\n  \"fr_summary\": \"Résumé de 2-3 phrases de l'acte juridique en français, du point de vue de son impact sur la vie quotidienne des citoyens.\",\n  \"fr_key_points\": [\n    \"Premier court point en français concernant les solutions ou changements les plus importants introduits.\",\n    \"Deuxième court point en français...\"\n  ],\n  \"es_ai_title\": \"Un nuevo título breve para el acto jurídico en español, que recoja la esencia de los cambios (por ejemplo, máximo 10-12 palabras).\",\n  \"es_summary\": \"Resumen de 2-3 frases del acto jurídico en español, desde la perspectiva de su impacto en la vida cotidiana de los ciudadanos.\",\n  \"es_key_points\": [\n    \"Primer punto breve en español sobre las soluciones o cambios más importantes que se introducen.\",\n    \"Segundo punto breve en español...\"\n  ],\n  \"it_ai_title\": \"Un nuovo titolo breve per l'atto giuridico in italiano, che colga l'essenza delle modifiche (ad es. massimo 10-12 parole).\",\n  \"it_summary\": \"Riepilogo di 2-3 frasi dell'atto giuridico in italiano, dal punto di vista del suo impatto sulla vita quotidiana dei cittadini.\",\n  \"it_key_points\": [\n    \"Primo breve punto in italiano riguardante le soluzioni o le modifiche più importanti introdotte.\",\n    \"Secondo breve punto in italiano...\"\n  ],\n  \"nl_ai_title\": \"Een nieuwe, korte titel voor de rechtshandeling in het Nederlands, die de essentie van de wijzigingen weergeeft (bijv. max. 10-12 woorden).\",\n  \"nl_summary\": \"Samenvatting van 2-3 zinnen van de rechtshandeling in het Nederlands, vanuit het perspectief van de impact op het dagelijks leven van burgers.\",\n  \"nl_key_points\": [\n    \"Eerste korte punt in het Nederlands betreffende de belangrijkste geïntroduceerde oplossingen of wijzigingen.\",\n    \"Tweede korte punt in het Nederlands...\"\n  ],\n  \"pt_ai_title\": \"Um novo título curto para o ato jurídico em português, capturando a essência das mudanças (por exemplo, máx. 10-12 palavras).\",\n  \"pt_summary\": \"Resumo de 2-3 frases do ato jurídico em português, na perspetiva do seu impacto na vida quotidiana dos cidadãos.\",\n  \"pt_key_points\": [\n    \"Primeiro ponto curto em português sobre as soluções ou alterações mais importantes introduzidas.\",\n    \"Segundo ponto curto em português...\"\n  ],\n  \"category\": [\"Categorize the document into one category by default, based on the field it primarily concerns. Choose up to 3 if the document also touches upon SIGNIFICANT issues from other categories. You MUST select categories ONLY from the following list: Health, Education, Family, Taxes, Labor, Security, Environment, Courts and Law, Transport, Benefits, Real Estate, Media and Culture, Local Government, Migration, Agriculture, Public Investments, Informatization, Economy. If the document does not definitively fit any of these, you MUST use \"Other\". If you use \"Other\", it should be the ONLY category selected. Do NOT invent new categories. The response must be an array of strings, e.g., [\"Taxes\", \"Family\"].\"]\n}\n\n",
      "ai_response_raw": "{\n  \"pl_ai_title\": \"Nowoczesne terapie zdrowia psychicznego dla weteranów: nowe biuro i innowacyjne leczenie\",\n  \"pl_summary\": \"Ustawa powołuje specjalne Biuro Nowoczesnych Terapii, które przygotuje system opieki nad weteranami do bezpiecznego wdrażania innowacyjnych metod leczenia, takich jak terapie wspomagane psychodelikami. Zmiany mają na celu zapewnienie szybszego dostępu do nowoczesnej pomocy w przypadku depresji, stresu pourazowego i innych schorzeń psychicznych.\",\n  \"pl_key_points\": [\n    \"Utworzenie Biura Nowoczesnych Terapii w ramach administracji zdrowia weteranów.\",\n    \"Opracowanie standardów dla nowych metod leczenia, w tym terapii wymagających intensywnej opieki klinicznej.\",\n    \"Powołanie komitetu doradczego złożonego z weteranów i ich rodzin, aby mieli wpływ na projektowanie opieki.\",\n    \"Wyznaczenie specjalistycznych centrów doskonałości zajmujących się badaniami i szkoleniami w zakresie nowych terapii.\",\n    \"Zapewnienie ciągłości opieki poprzez wsparcie rówieśnicze i współpracę z organizacjami lokalnymi.\"\n  ],\n  \"eng_ai_title\": \"Modern Mental Health Therapies for Veterans: New Office and Innovative Treatments\",\n  \"eng_summary\": \"The act establishes a dedicated Office of Novel Therapeutics to prepare the veterans' healthcare system for the safe implementation of innovative treatments, such as psychedelic-assisted therapies. These changes aim to provide faster access to modern help for depression, PTSD, and other mental health conditions.\",\n  \"eng_key_points\": [\n    \"Establishment of the Office of Novel Therapeutics within the Veterans Health Administration.\",\n    \"Development of standards for new treatment methods, including therapies requiring intensive clinical care.\",\n    \"Creation of a veteran advisory committee to give veterans and their families a voice in care design.\",\n    \"Designation of specialized centers of excellence for research and training in novel therapies.\",\n    \"Ensuring continuity of care through peer support and coordination with community organizations.\"\n  ],\n  \"de_ai_title\": \"Moderne psychische Therapien für Veteranen: Neues Büro und innovative Behandlungen\",\n  \"de_summary\": \"Das Gesetz richtet ein spezielles Büro für neuartige Therapeutika ein, um das Gesundheitssystem für Veteranen auf die sichere Einführung innovativer Behandlungen, wie etwa psychedelisch unterstützte Therapien, vorzubereiten. Ziel ist ein schnellerer Zugang zu moderner Hilfe bei Depressionen, PTBS und anderen psychischen Erkrankungen.\",\n  \"de_key_points\": [\n    \"Einrichtung des Büros für neuartige Therapeutika innerhalb der Veterans Health Administration.\",\n    \"Entwicklung von Standards für neue Behandlungsmethoden, die eine intensive klinische Betreuung erfordern.\",\n    \"Einsetzung eines Beratungsausschusses aus Veteranen und deren Familien zur Mitgestaltung der Versorgung.\",\n    \"Ausweisung spezialisierter Kompetenzzentren für Forschung und Ausbildung in neuen Therapien.\",\n    \"Sicherstellung der Kontinuität der Versorgung durch Peer-Support und Zusammenarbeit mit lokalen Organisationen.\"\n  ],\n  \"fr_ai_title\": \"Thérapies modernes de santé mentale pour les vétérans : nouveau bureau et traitements innovants\",\n  \"fr_summary\": \"La loi crée un Bureau des Thérapeutiques Nouvelles pour préparer le système de santé des vétérans à la mise en œuvre sécurisée de traitements innovants, tels que les thérapies assistées par des psychédéliques. Ces changements visent à offrir un accès plus rapide à une aide moderne pour la dépression, le SSPT et d'autres troubles mentaux.\",\n  \"fr_key_points\": [\n    \"Création du Bureau des Thérapeutiques Nouvelles au sein de l'administration de la santé des vétérans.\",\n    \"Élaboration de normes pour les nouvelles méthodes de traitement nécessitant des soins cliniques intensifs.\",\n    \"Mise en place d'un comité consultatif de vétérans pour permettre aux patients et à leurs familles d'influencer les soins.\",\n    \"Désignation de centres d'excellence spécialisés dans la recherche et la formation aux nouvelles thérapies.\",\n    \"Garantie de la continuité des soins grâce au soutien par les pairs et à la coordination avec des organismes locaux.\"\n  ],\n  \"es_ai_title\": \"Terapias modernas de salud mental para veteranos: nueva oficina y tratamientos innovadores\",\n  \"es_summary\": \"La ley establece una Oficina de Terapéuticas Novedosas para preparar el sistema de salud de los veteranos para la implementación segura de tratamientos innovadores, como las terapias asistidas por psicodélicos. Estos cambios buscan brindar un acceso más rápido a ayuda moderna para la depresión, el TEPT y otras afecciones mentales.\",\n  \"es_key_points\": [\n    \"Creación de la Oficina de Terapéuticas Novedosas dentro de la Administración de Salud de Veteranos.\",\n    \"Desarrollo de estándares para nuevos métodos de tratamiento que requieren atención clínica intensiva.\",\n    \"Creación de un comité asesor de veteranos para que los pacientes y sus familias influyan en el diseño de la atención.\",\n    \"Designación de centros de excelencia especializados en investigación y capacitación en nuevas terapias.\",\n    \"Garantía de la continuidad de la atención mediante el apoyo de pares y la coordinación con organizaciones locales.\"\n  ],\n  \"it_ai_title\": \"Terapie moderne per la salute mentale dei veterani: nuovo ufficio e trattamenti innovativi\",\n  \"it_summary\": \"La legge istituisce un Ufficio per le Nuove Terapie per preparare il sistema sanitario dei veterani all'implementazione sicura di trattamenti innovativi, come le terapie assistite da psichedelici. Questi cambiamenti mirano a fornire un accesso più rapido a cure moderne per depressione, PTSD e altri disturbi mentali.\",\n  \"it_key_points\": [\n    \"Istituzione dell'Ufficio per le Nuove Terapie all'interno della Veterans Health Administration.\",\n    \"Sviluppo di standard per nuovi metodi di trattamento che richiedono un'assistenza clinica intensiva.\",\n    \"Creazione di un comitato consultivo di veterani per dare voce ai pazienti e alle loro famiglie nella progettazione delle cure.\",\n    \"Designazione di centri di eccellenza specializzati nella ricerca e nella formazione sulle nuove terapie.\",\n    \"Garanzia della continuità delle cure attraverso il supporto tra pari e il coordinamento con le organizzazioni locali.\"\n  ],\n  \"nl_ai_title\": \"Moderne geestelijke gezondheidszorg voor veteranen: nieuw bureau en innovatieve behandelingen\",\n  \"nl_summary\": \"De wet richt een Bureau voor Nieuwe Therapeutica op om de gezondheidszorg voor veteranen voor te bereiden op de veilige invoering van innovatieve behandelingen, zoals psychedelisch ondersteunde therapieën. Deze wijzigingen zijn bedoeld om snellere toegang te bieden tot moderne hulp bij depressie, PTSS en andere psychische aandoeningen.\",\n  \"nl_key_points\": [\n    \"Oprichting van het Bureau voor Nieuwe Therapeutica binnen de Veterans Health Administration.\",\n    \"Ontwikkeling van normen voor nieuwe behandelmethoden die intensieve klinische zorg vereisen.\",\n    \"Instelling van een adviescommissie van veteranen zodat patiënten en hun families invloed hebben op de zorg.\",\n    \"Aanwijzing van gespecialiseerde expertisecentra voor onderzoek naar en training in nieuwe therapieën.\",\n    \"Waarborgen van continuïteit van zorg via ondersteuning door lotgenoten en samenwerking met lokale organisaties.\"\n  ],\n  \"pt_ai_title\": \"Terapias modernas de saúde mental para veteranos: novo gabinete e tratamentos inovadores\",\n  \"pt_summary\": \"A lei estabelece um Gabinete de Novas Terapêuticas para preparar o sistema de saúde dos veteranos para a implementação segura de tratamentos inovadores, como terapias assistidas por psicadélicos. Estas mudanças visam proporcionar um acesso mais rápido a ajuda moderna para depressão, stress pós-traumático e outras condições mentais.\",\n  \"pt_key_points\": [\n    \"Criação do Gabinete de Novas Terapêuticas na Administração de Saúde dos Veteranos.\",\n    \"Desenvolvimento de normas para novos métodos de tratamento que exijam cuidados clínicos intensivos.\",\n    \"Criação de um comité consultivo de veteranos para que os doentes e as suas famílias influenciem o design dos cuidados.\",\n    \"Designação de centros de excelência especializados em investigação e formação em novas terapias.\",\n    \"Garantia da continuidade dos cuidados através do apoio de pares e coordenação com organizações locais.\"\n  ],\n  \"category\": [\"Health\"]\n}"
    },
    {
      "timestamp": "2026-04-13T14:24:07.432Z",
      "source_url": "https://www.congress.gov/119/bills/s4220/BILLS-119s4220is.htm",
      "model": "gemini-flash-latest",
      "prompt_sent": "\nJesteś ekspertem od prawa Stanów Zjednoczonych, który ma za zadanie analizować dokumenty ustaw, uchwał oraz innych dokumentów legislacyjnych, a następnie przygotowywać z nich informacje w przystępny sposób dla obywateli. Twoim celem jest przedstawienie informacji tak, aby obywatele mogli sami ocenić wpływ legislacji na ich życie, nawet bez posiadania specjalistycznej wiedzy legislacyjnej. Skup się na faktach i obiektywnych skutkach wprowadzanych zmian, unikając wartościowania i osobistych opinii. Wszelki żargon prawny jest zabroniony. Prezentuj informacje w jasny, zwięzły i angażujący sposób, tak aby były zrozumiałe dla osoby bez wykształcenia prawniczego. Unikaj długich, złożonych zdań. Zamiast pisać \"projekt ma na celu nowelizację kodeksu podatkowego...\", napisz \"Zmiany w podatkach: nowe ulgi i obowiązki dla...\". Kontynuuj swoją pracę, dopóki nie rozwiążesz swojego zadania. Jeśli nie masz pewności co do generowanej treści, przeanalizuj dokument ponownie – nie zgaduj. Rozplanuj dobrze swoje zadanie przed przystąpieniem do niego. W podsumowaniu i kluczowych punktach, jeśli to możliwe i uzasadnione, podkreśl, jakie konkretne korzyści lub skutki (pozytywne lub negatywne) wprowadza ustawa dla życia codziennego obywateli, ich praw i obowiązków, finansów osobistych, bezpieczeństwa i innych ważnych kwestii (np. kategorycznych zakazów i nakazów czy najważniejszych konkretnych alokacji finansowych i terytorialnych).\n\nTwoja odpowiedź MUSI być w formacie JSON - i zawierać następujące klucze.\nZanim zwrócisz odpowiedź, dokładnie zweryfikuj, czy cała struktura JSON jest w 100% poprawna, włącznie ze wszystkimi przecinkami, nawiasami klamrowymi, kwadratowymi oraz cudzysłowami. Błędny JSON jest nieakceptowalny i uniemożliwi przetworzenie Twojej pracy.\n\nPrzeanalizuj dokładnie poniższy tekst dokumentu prawnego. To jest treść, na podstawie której masz wygenerować podsumowanie i kluczowe punkty:\n--- POCZĄTEK DOKUMENTU ---\n[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [S. 4220 Introduced in Senate (IS)] <DOC> 119th CONGRESS 2d Session S. 4220 To amend title 38, United States Code, to establish within the Veterans Health Administration an Office of Novel Therapeutics, and for other purposes. _______________________________________________________________________ IN THE SENATE OF THE UNITED STATES March 26, 2026 Mr. Sheehy (for himself, Mr. Gallego, Ms. Duckworth, and Mr. Boozman) introduced the following bill; which was read twice and referred to the Committee on Veterans' Affairs _______________________________________________________________________ A BILL To amend title 38, United States Code, to establish within the Veterans Health Administration an Office of Novel Therapeutics, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Veterans Health Administration Novel Therapeutics Preparedness Act''. SEC. 2. FINDINGS. Congress finds the following: (1) Emerging therapeutic interventions, including certain psychedelic-assisted therapies under evaluation by the Food and Drug Administration as of the date of the enactment of this Act, may significantly alter the treatment landscape for post- traumatic stress disorder, depression, and other mental health conditions affecting veterans. (2) The administration of certain emerging therapies may require intensive clinical engagement, interdisciplinary teams, dedicated clinical space, structured preparation, and post- treatment integration that differ substantially from traditional outpatient mental health services. (3) The Department of Veterans Affairs is uniquely positioned to deliver integrated, veteran-centered care that combines medical, mental health, and peer support services within a single system of care. (4) Absent centralized governance and implementation planning, the Department may face delays, safety risks, or inconsistent access following regulatory approval of such therapies. (5) Establishing a dedicated Office of Novel Therapeutics will ensure that the Department is prepared to responsibly evaluate, research, and implement emerging treatment modalities consistent with patient safety and evidence-based practice. SEC. 3. ESTABLISHMENT OF OFFICE OF NOVEL THERAPEUTICS WITHIN VETERANS HEALTH ADMINISTRATION. (a) Establishment.-- (1) In general.--Chapter 73 of title 38, United States Code, is amended by adding at the end the following new subchapter: ``Subchapter VI--Novel Therapeutics ``Sec. 7391. Definitions ``In this subchapter: ``(1) Center of excellence.--The term `center of excellence' means a medical center of the Department designated under section 7394 of this title as a center of excellence for novel therapeutics to advance research, training, and implementation of emerging therapeutic interventions. ``(2) Emerging therapeutic intervention.--The term `emerging therapeutic intervention' means a pharmacological, biological, or other therapeutic modality under evaluation or review by the Food and Drug Administration. ``Sec. 7392. Office of Novel Therapeutics ``(a) Establishment.--There is established within the Veterans Health Administration, under the Office of the Under Secretary for Health, an Office of Novel Therapeutics (in this section referred to as the `Office'). ``(b) Director.--The head of the Office shall be the Director of the Office of Novel Therapeutics, who shall be appointed by the Under Secretary for Health and who shall-- ``(1) possess demonstrated expertise in clinical research and implementation science; and ``(2) report directly to the Under Secretary for Health. ``(c) Coordinating Authority.--The Office shall serve as the primary coordinating authority within the Veterans Health Administration for matters relating to emerging and novel therapeutic interventions. ``(d) Duties.--The Office shall-- ``(1) develop and oversee national policy, guidance, and clinical standards for the evaluation, research, and potential implementation by the Veterans Health Administration of emerging and novel therapeutic interventions for mental health conditions affecting veterans; ``(2) develop a national clinical model for the administration of intensive therapeutic interventions, including structured preparation, monitored administration, and post-administration integration; ``(3) develop guidance regarding patient eligibility and candidacy for emerging therapeutic interventions, ensuring that utilization management or step therapy requirements do not unduly restrict access where clinically appropriate; ``(4) develop implementation-readiness plans for therapies that may receive approval from the Food and Drug Administration, including-- ``(A) facility infrastructure requirements; ``(B) interdisciplinary team composition standards; ``(C) allocation of protected clinical time necessary to safely administer intensive therapeutic interventions, including full session and integration requirements; ``(D) patient safety and adverse event monitoring and response protocols; and ``(E) integration with suicide prevention, post- traumatic stress disorder, and substance use disorder programs; ``(5) conduct a workforce-readiness assessment to identify clinicians and peer support specialists with prior training or certification relevant to emerging therapeutic interventions and gaps in training, supervision, and clinical capacity necessary to support safe and effective implementation of such interventions; ``(6) establish national training and credentialing standards for clinicians administering novel therapeutics; ``(7) develop a standardized, competency-based training framework for clinicians and peer support specialists participating in emerging therapeutic interventions, including preparation, monitored administration, integration, safety monitoring, interdisciplinary collaboration, and culturally competent care; ``(8) distinguish between research protocols and clinical implementation standards to ensure that patient care models are not constrained solely by sponsor-driven research design; ``(9) coordinate with the Office of Research and Development-- ``(A) to align research priorities with implementation-readiness needs; ``(B) to recommend specialized review pathways for research involving emerging therapeutic interventions; and ``(C) to develop standards for allocation of protected research time for clinicians participating in research involving emerging therapeutic interventions, including clarification that patients seen under approved research protocols shall be counted toward standard clinical productivity metrics; ``(10) develop guidance to ensure continuity of care, including-- ``(A) post-administration integration services; ``(B) incorporation of peer support specialists; and ``(C) coordination with community-based organizations for aftercare support as appropriate; ``(11) identify not fewer than one medical center in each Veterans Integrated Service Network to develop infrastructure and workforce-readiness for emerging therapeutic models; and ``(12) establish criteria for the designation of centers of excellence and oversee compliance with national standards. ``Sec. 7393. Clinical Implementation Program for Emerging Therapeutics ``(a) Establishment.--The Secretary, acting through the Office of Novel Therapeutics, shall establish a Clinical Implementation Program for Emerging Therapeutics (in this section referred to as the `Program') to evaluate the effectiveness, feasibility, safety, and scalability of emerging therapeutic interventions within the Department. ``(b) Purpose.--The Program shall-- ``(1) utilize effectiveness-implementation hybrid models to evaluate both clinical outcomes and real-world implementation factors with respect to emerging therapeutic interventions; ``(2) test and refine care delivery models, including patient eligibility criteria, safety protocols, interdisciplinary team models, and post-administration integration services; ``(3) generate real-world evidence to inform potential systemwide adoption; and ``(4) assess workforce, infrastructure, cost, and operational requirements necessary for broader implementation. ``(c) Covered Conditions.--In carrying out the Program, the Secretary may prioritize one or more brain or mental health conditions affecting veterans, including-- ``(1) post-traumatic stress disorder; ``(2) treatment-resistant depression; ``(3) substance use disorders; ``(4) suicidality; ``(5) traumatic brain injury; ``(6) repetitive low-level blast exposure; ``(7) chronic pain; ``(8) co-occurring conditions; and ``(9) other clinically appropriate conditions as determined appropriate by the Secretary. ``(d) Site Selection.--The Secretary may conduct the Program at-- ``(1) one or more centers of excellence; and ``(2) such other medical centers as the Secretary determines appropriate. ``Sec. 7394. Centers of excellence for novel therapeutics ``(a) Designation.--The Secretary may designate one or more medical centers of the Department as centers of excellence for novel therapeutics. ``(b) Functions.--Each center of excellence designated under subsection (a) shall-- ``(1) serve as a national leader in research, clinical training, and implementation of emerging therapeutic interventions; ``(2) develop and disseminate best practices and clinical standards across the Veterans Health Administration; ``(3) provide technical assistance and training to other medical centers of the Department; ``(4) integrate interdisciplinary care models, including peer support and post-administration integration services; ``(5) incorporate veteran advisory input into program development; and ``(6) coordinate with academic affiliates and external research partners, as appropriate. ``(c) Coordination.--Centers of excellence designated under subsection (a) shall operate in coordination with, and under standards established by, the Office of Novel Therapeutics. ``Sec. 7395. Veteran Advisory Committee on Novel Therapeutics ``(a) Establishment.--The Secretary shall establish a Veteran Advisory Committee on Novel Therapeutics (in this section referred to as the `Committee') to advise the Office of Novel Therapeutics. ``(b) Membership.--The Secretary shall select the members of the Committee, which shall include the following: ``(1) Veterans with lived experience of mental health treatment furnished by the Department. ``(2) Veterans who have participated in clinical research involving emerging therapeutic interventions, as applicable. ``(3) Family members or caregivers of veterans described in paragraph (1) or (2). ``(4) Representatives from academic institutions affiliated with the Department with expertise in clinical research, behavioral health, or emerging therapeutic interventions. ``(5) Subject matter experts as determined appropriate by the Secretary. ``(c) Duties.--With respect to the use of novel therapeutics, the Committee shall provide input on-- ``(1) patient safety considerations; ``(2) informed consent practices; ``(3) implementation and access barriers; and ``(4) patient-centered care design. ``Sec. 7396. Interagency coordination ``In carrying out this subchapter, the Secretary shall coordinate with the Secretary of Health and Human Services, the Commissioner of Food and Drugs, the Administrator of the Centers for Medicare & Medicaid Services, the Secretary of Defense, and the Administrator of the Drug Enforcement Administration to support-- ``(1) regulatory readiness; ``(2) development of reimbursement and billing pathways; ``(3) scheduling and rescheduling considerations, as appropriate; and ``(4) shared data infrastructure for monitoring safety, quality, and outcomes. ``Sec. 7397. Annual report ``Not less frequently than annually, the Secretary shall submit to Congress a report describing-- ``(1) research activities of the Department relating to emerging therapeutic interventions; ``(2) clinical outcomes and patient-reported outcomes under the Clinical Implementation Program for Emerging Therapeutics under section 7393 of this title; ``(3) safety events and adverse outcomes; ``(4) workforce readiness and training capacity; ``(5) implementation barriers, including staffing, procurement, and infrastructure needs; and ``(6) recommendations for legislative or administrative action relating to novel therapeutics.''. (2) Clerical amendment.--The table of sections at the beginning of chapter 73 of such title is amended by adding at the end the following: ``subchapter vi--novel therapeutics ``Sec. ``7391. Definitions. ``7392. Office of Novel Therapeutics. ``7393. Clinical Implementation Program for Emerging Therapeutics. ``7394. Centers of excellence for novel therapeutics. ``7395. Veteran Advisory Committee on Novel Therapeutics. ``7396. Interagency coordination. ``7397. Annual report.''. (b) National Preparedness and Implementation Strategy.--Not later than 180 days after the date of the enactment of this Act, the Secretary of Veterans Affairs shall submit to Congress a national preparedness and implementation strategy of the Veterans Health Administration for emerging mental health therapeutics, including-- (1) workforce capacity assessments; (2) facility modification needs; (3) projected timelines for phased implementation; and (4) barriers to implementation. <all>\n--- KONIEC DOKUMENTU ---\n\nPAMIĘTAJ: Twoja odpowiedź MUSI być wyłącznie poprawnym obiektem JSON. Nie dodawaj żadnych dodatkowych znaków, komentarzy ani tekstu przed znacznikiem '{' ani po znaczniku '}'. Cała odpowiedź musi być parsowalna jako JSON.\nNa podstawie POWYŻSZEGO dokumentu, wypełnij poniższą strukturę JSON:\nOto struktura JSON, której oczekuję (wypełnij ją treścią):\n{\n  \"pl_ai_title\": \"Nowy, krótki tytuł dla aktu prawnego po polsku, oddający sedno wprowadzanych zmian (np. maksymalnie 10-12 słów).\",\n  \"pl_summary\": \"2-3 zdania zwięzłego podsumowania treści aktu prawnego po polsku, napisane z perspektywy wpływu na życie codzienne obywateli.\",\n  \"pl_key_points\": [\n    \"Pierwszy krótki punkt po polsku dotyczący najważniejszych wprowadzanych rozwiązań lub zmian.\",\n    \"Drugi krótki punkt po polsku...\"\n  ],\n  \"eng_ai_title\": \"A new, short title for the legal act in English, capturing the essence of the changes (e.g., max 10-12 words).\",\n  \"eng_summary\": \"2-3 sentences summarizing the legal act in English, from the perspective of its impact on citizens' daily lives.\",\n  \"eng_key_points\": [\n    \"First short bullet point in English regarding the most important solutions or changes being introduced.\",\n    \"Second short bullet point in English...\"\n  ],\n  \"de_ai_title\": \"Ein neuer, kurzer Titel für das Rechtsdokument auf Deutsch, der den Kern der Änderungen erfasst (z.B. max. 10-12 Wörter).\",\n  \"de_summary\": \"2-3 Sätze Zusammenfassung des Rechtsdokuments auf Deutsch, aus der Perspektive seiner Auswirkungen auf das tägliche Leben der Bürger.\",\n  \"de_key_points\": [\n    \"Erster kurzer Stichpunkt auf Deutsch zu den wichtigsten eingeführten Lösungen oder Änderungen.\",\n    \"Zweiter kurzer Stichpunkt auf Deutsch...\"\n  ],\n  \"fr_ai_title\": \"Un nouveau titre court pour l'acte juridique en français, saisissant l'essence des changements (par exemple, 10-12 mots maximum).\",\n  \"fr_summary\": \"Résumé de 2-3 phrases de l'acte juridique en français, du point de vue de son impact sur la vie quotidienne des citoyens.\",\n  \"fr_key_points\": [\n    \"Premier court point en français concernant les solutions ou changements les plus importants introduits.\",\n    \"Deuxième court point en français...\"\n  ],\n  \"es_ai_title\": \"Un nuevo título breve para el acto jurídico en español, que recoja la esencia de los cambios (por ejemplo, máximo 10-12 palabras).\",\n  \"es_summary\": \"Resumen de 2-3 frases del acto jurídico en español, desde la perspectiva de su impacto en la vida cotidiana de los ciudadanos.\",\n  \"es_key_points\": [\n    \"Primer punto breve en español sobre las soluciones o cambios más importantes que se introducen.\",\n    \"Segundo punto breve en español...\"\n  ],\n  \"it_ai_title\": \"Un nuovo titolo breve per l'atto giuridico in italiano, che colga l'essenza delle modifiche (ad es. massimo 10-12 parole).\",\n  \"it_summary\": \"Riepilogo di 2-3 frasi dell'atto giuridico in italiano, dal punto di vista del suo impatto sulla vita quotidiana dei cittadini.\",\n  \"it_key_points\": [\n    \"Primo breve punto in italiano riguardante le soluzioni o le modifiche più importanti introdotte.\",\n    \"Secondo breve punto in italiano...\"\n  ],\n  \"nl_ai_title\": \"Een nieuwe, korte titel voor de rechtshandeling in het Nederlands, die de essentie van de wijzigingen weergeeft (bijv. max. 10-12 woorden).\",\n  \"nl_summary\": \"Samenvatting van 2-3 zinnen van de rechtshandeling in het Nederlands, vanuit het perspectief van de impact op het dagelijks leven van burgers.\",\n  \"nl_key_points\": [\n    \"Eerste korte punt in het Nederlands betreffende de belangrijkste geïntroduceerde oplossingen of wijzigingen.\",\n    \"Tweede korte punt in het Nederlands...\"\n  ],\n  \"pt_ai_title\": \"Um novo título curto para o ato jurídico em português, capturando a essência das mudanças (por exemplo, máx. 10-12 palavras).\",\n  \"pt_summary\": \"Resumo de 2-3 frases do ato jurídico em português, na perspetiva do seu impacto na vida quotidiana dos cidadãos.\",\n  \"pt_key_points\": [\n    \"Primeiro ponto curto em português sobre as soluções ou alterações mais importantes introduzidas.\",\n    \"Segundo ponto curto em português...\"\n  ],\n  \"category\": [\"Categorize the document into one category by default, based on the field it primarily concerns. Choose up to 3 if the document also touches upon SIGNIFICANT issues from other categories. You MUST select categories ONLY from the following list: Health, Education, Family, Taxes, Labor, Security, Environment, Courts and Law, Transport, Benefits, Real Estate, Media and Culture, Local Government, Migration, Agriculture, Public Investments, Informatization, Economy. If the document does not definitively fit any of these, you MUST use \"Other\". If you use \"Other\", it should be the ONLY category selected. Do NOT invent new categories. The response must be an array of strings, e.g., [\"Taxes\", \"Family\"].\"]\n}\n\n",
      "ai_response_raw": "{\n  \"pl_ai_title\": \"Nowoczesne terapie zdrowia psychicznego dla weteranów: nowe biuro i innowacyjne leczenie\",\n  \"pl_summary\": \"Ustawa powołuje specjalne Biuro Nowoczesnych Terapii, które przygotuje system opieki nad weteranami do bezpiecznego wdrażania innowacyjnych metod leczenia, takich jak terapie wspomagane psychodelikami. Zmiany mają na celu zapewnienie szybszego dostępu do nowoczesnej pomocy w przypadku depresji, stresu pourazowego i innych schorzeń psychicznych.\",\n  \"pl_key_points\": [\n    \"Utworzenie Biura Nowoczesnych Terapii w ramach administracji zdrowia weteranów.\",\n    \"Opracowanie standardów dla nowych metod leczenia, w tym terapii wymagających intensywnej opieki klinicznej.\",\n    \"Powołanie komitetu doradczego złożonego z weteranów i ich rodzin, aby mieli wpływ na projektowanie opieki.\",\n    \"Wyznaczenie specjalistycznych centrów doskonałości zajmujących się badaniami i szkoleniami w zakresie nowych terapii.\",\n    \"Zapewnienie ciągłości opieki poprzez wsparcie rówieśnicze i współpracę z organizacjami lokalnymi.\"\n  ],\n  \"eng_ai_title\": \"Modern Mental Health Therapies for Veterans: New Office and Innovative Treatments\",\n  \"eng_summary\": \"The act establishes a dedicated Office of Novel Therapeutics to prepare the veterans' healthcare system for the safe implementation of innovative treatments, such as psychedelic-assisted therapies. These changes aim to provide faster access to modern help for depression, PTSD, and other mental health conditions.\",\n  \"eng_key_points\": [\n    \"Establishment of the Office of Novel Therapeutics within the Veterans Health Administration.\",\n    \"Development of standards for new treatment methods, including therapies requiring intensive clinical care.\",\n    \"Creation of a veteran advisory committee to give veterans and their families a voice in care design.\",\n    \"Designation of specialized centers of excellence for research and training in novel therapies.\",\n    \"Ensuring continuity of care through peer support and coordination with community organizations.\"\n  ],\n  \"de_ai_title\": \"Moderne psychische Therapien für Veteranen: Neues Büro und innovative Behandlungen\",\n  \"de_summary\": \"Das Gesetz richtet ein spezielles Büro für neuartige Therapeutika ein, um das Gesundheitssystem für Veteranen auf die sichere Einführung innovativer Behandlungen, wie etwa psychedelisch unterstützte Therapien, vorzubereiten. Ziel ist ein schnellerer Zugang zu moderner Hilfe bei Depressionen, PTBS und anderen psychischen Erkrankungen.\",\n  \"de_key_points\": [\n    \"Einrichtung des Büros für neuartige Therapeutika innerhalb der Veterans Health Administration.\",\n    \"Entwicklung von Standards für neue Behandlungsmethoden, die eine intensive klinische Betreuung erfordern.\",\n    \"Einsetzung eines Beratungsausschusses aus Veteranen und deren Familien zur Mitgestaltung der Versorgung.\",\n    \"Ausweisung spezialisierter Kompetenzzentren für Forschung und Ausbildung in neuen Therapien.\",\n    \"Sicherstellung der Kontinuität der Versorgung durch Peer-Support und Zusammenarbeit mit lokalen Organisationen.\"\n  ],\n  \"fr_ai_title\": \"Thérapies modernes de santé mentale pour les vétérans : nouveau bureau et traitements innovants\",\n  \"fr_summary\": \"La loi crée un Bureau des Thérapeutiques Nouvelles pour préparer le système de santé des vétérans à la mise en œuvre sécurisée de traitements innovants, tels que les thérapies assistées par des psychédéliques. Ces changements visent à offrir un accès plus rapide à une aide moderne pour la dépression, le SSPT et d'autres troubles mentaux.\",\n  \"fr_key_points\": [\n    \"Création du Bureau des Thérapeutiques Nouvelles au sein de l'administration de la santé des vétérans.\",\n    \"Élaboration de normes pour les nouvelles méthodes de traitement nécessitant des soins cliniques intensifs.\",\n    \"Mise en place d'un comité consultatif de vétérans pour permettre aux patients et à leurs familles d'influencer les soins.\",\n    \"Désignation de centres d'excellence spécialisés dans la recherche et la formation aux nouvelles thérapies.\",\n    \"Garantie de la continuité des soins grâce au soutien par les pairs et à la coordination avec des organismes locaux.\"\n  ],\n  \"es_ai_title\": \"Terapias modernas de salud mental para veteranos: nueva oficina y tratamientos innovadores\",\n  \"es_summary\": \"La ley establece una Oficina de Terapéuticas Novedosas para preparar el sistema de salud de los veteranos para la implementación segura de tratamientos innovadores, como las terapias asistidas por psicodélicos. Estos cambios buscan brindar un acceso más rápido a ayuda moderna para la depresión, el TEPT y otras afecciones mentales.\",\n  \"es_key_points\": [\n    \"Creación de la Oficina de Terapéuticas Novedosas dentro de la Administración de Salud de Veteranos.\",\n    \"Desarrollo de estándares para nuevos métodos de tratamiento que requieren atención clínica intensiva.\",\n    \"Creación de un comité asesor de veteranos para que los pacientes y sus familias influyan en el diseño de la atención.\",\n    \"Designación de centros de excelencia especializados en investigación y capacitación en nuevas terapias.\",\n    \"Garantía de la continuidad de la atención mediante el apoyo de pares y la coordinación con organizaciones locales.\"\n  ],\n  \"it_ai_title\": \"Terapie moderne per la salute mentale dei veterani: nuovo ufficio e trattamenti innovativi\",\n  \"it_summary\": \"La legge istituisce un Ufficio per le Nuove Terapie per preparare il sistema sanitario dei veterani all'implementazione sicura di trattamenti innovativi, come le terapie assistite da psichedelici. Questi cambiamenti mirano a fornire un accesso più rapido a cure moderne per depressione, PTSD e altri disturbi mentali.\",\n  \"it_key_points\": [\n    \"Istituzione dell'Ufficio per le Nuove Terapie all'interno della Veterans Health Administration.\",\n    \"Sviluppo di standard per nuovi metodi di trattamento che richiedono un'assistenza clinica intensiva.\",\n    \"Creazione di un comitato consultivo di veterani per dare voce ai pazienti e alle loro famiglie nella progettazione delle cure.\",\n    \"Designazione di centri di eccellenza specializzati nella ricerca e nella formazione sulle nuove terapie.\",\n    \"Garanzia della continuità delle cure attraverso il supporto tra pari e il coordinamento con le organizzazioni locali.\"\n  ],\n  \"nl_ai_title\": \"Moderne geestelijke gezondheidszorg voor veteranen: nieuw bureau en innovatieve behandelingen\",\n  \"nl_summary\": \"De wet richt een Bureau voor Nieuwe Therapeutica op om de gezondheidszorg voor veteranen voor te bereiden op de veilige invoering van innovatieve behandelingen, zoals psychedelisch ondersteunde therapieën. Deze wijzigingen zijn bedoeld om snellere toegang te bieden tot moderne hulp bij depressie, PTSS en andere psychische aandoeningen.\",\n  \"nl_key_points\": [\n    \"Oprichting van het Bureau voor Nieuwe Therapeutica binnen de Veterans Health Administration.\",\n    \"Ontwikkeling van normen voor nieuwe behandelmethoden die intensieve klinische zorg vereisen.\",\n    \"Instelling van een adviescommissie van veteranen zodat patiënten en hun families invloed hebben op de zorg.\",\n    \"Aanwijzing van gespecialiseerde expertisecentra voor onderzoek naar en training in nieuwe therapieën.\",\n    \"Waarborgen van continuïteit van zorg via ondersteuning door lotgenoten en samenwerking met lokale organisaties.\"\n  ],\n  \"pt_ai_title\": \"Terapias modernas de saúde mental para veteranos: novo gabinete e tratamentos inovadores\",\n  \"pt_summary\": \"A lei estabelece um Gabinete de Novas Terapêuticas para preparar o sistema de saúde dos veteranos para a implementação segura de tratamentos inovadores, como terapias assistidas por psicadélicos. Estas mudanças visam proporcionar um acesso mais rápido a ajuda moderna para depressão, stress pós-traumático e outras condições mentais.\",\n  \"pt_key_points\": [\n    \"Criação do Gabinete de Novas Terapêuticas na Administração de Saúde dos Veteranos.\",\n    \"Desenvolvimento de normas para novos métodos de tratamento que exijam cuidados clínicos intensivos.\",\n    \"Criação de um comité consultivo de veteranos para que os doentes e as suas famílias influenciem o design dos cuidados.\",\n    \"Designação de centros de excelência especializados em investigação e formação em novas terapias.\",\n    \"Garantia da continuidade dos cuidados através do apoio de pares e coordenação com organizações locais.\"\n  ],\n  \"category\": [\"Health\"]\n}"
    }
  ]
}